---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-030393"
form_type: "8-K"
ticker: "TWST"
cik: "0001581280"
company_name: "Twist Bioscience Corp"
filed_at: "2022-11-18T23:59:59+00:00"
generated_at: "2026-06-21T15:50:50.849031+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Twist Bioscience reports FY2022 revenue $203.6M (+54% YoY); guides FY2023 revenue $261-269M

## Summary
- FY2022 revenue $203.6M, up 54% YoY; net loss $217.9M ($4.04/share) vs $152.1M loss in FY2021.
- Q4 FY2022 revenue $57.3M (up 51% YoY); net loss $51.1M ($0.91/share).
- Full year orders $226M, up 42% YoY; shipped 558,000 genes vs 372,000 in FY2021.
- FY2023 revenue guidance $261-269M; FY2024 target $350M.
- Promoted Patrick Finn, Ph.D. to president and COO; partnered with Illumina and PacBio.

## SEC filing metadata
- accession: 0001628280-22-030393
- form_type: 8-K
- ticker: TWST
- cik: 0001581280
- company_name: Twist Bioscience Corp
- filed_at: 2022-11-18T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1581280/000162828022030393/0001628280-22-030393-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1581280/000162828022030393/twist-20221118.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-030393
- JSON: https://secwatch.observer/filing/0001628280-22-030393.json
- Plain text: https://secwatch.observer/filing/0001628280-22-030393.txt

## Key facts
- Earnings Releases
  Twist Bioscience Corp reported fiscal year ended September 30, 2022 results: revenue $203.6 million, net income $217.9 million, EPS $4.04 per share. Guidance initiated.
  - Period: fiscal year ended September 30, 2022
  - Revenue: $203.6 million
  - Net income: $217.9 million
  - EPS: $4.04 per share
  - Guidance: initiated
  - Result: reported results
  source text: FISCAL 2022 FINANCIAL RESULTS • Orders : Total orders received for fiscal 2022 were $226 million compared to $159.5 million for fiscal 2021. • Revenue : Total revenues for fiscal 2022 were $203.6 million compared to $132.3 million for fiscal 2021. • Cost of Revenues : Cost of revenues for fiscal 2022 was $119.3 million compared to $80.6 million for fiscal 2021. • Research and Development Expenses : Research and development expenses for fiscal 2022 were $120.3 million compared to $69.1 million for fiscal 2021. • Selling, General and Administrative Expenses: Selling, general and administrative expenses for fiscal 2022 were $212.9 million compared to $135.9 million for fiscal 2021. • Net Loss: Net loss attributable to common stockholders for fiscal 2022 was $217.9 million , or $4.04 per share, compared to $152.1 million , or $3.15 per share, for fiscal 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1581280/000162828022030393/0001628280-22-030393-index.htm
- Earnings Releases
  Twist Bioscience Corp reported the fourth quarter of fiscal 2022 results: revenue $57.3 million, net income $51.1 million, EPS $0.91 per share. Guidance initiated.
  - Period: the fourth quarter of fiscal 2022
  - Revenue: $57.3 million
  - Net income: $51.1 million
  - EPS: $0.91 per share
  - Guidance: initiated
  - Result: reported results
  source text: FISCAL 2022 FOURTH QUARTER FINANCIAL RESULTS • Orders: Total orders received for the fourth quarter of fiscal 2022 were $62.1 million compared to $45.2 million for the same period of fiscal 2021 . • Revenue: Total revenues for the fourth quarter of fiscal 2022 were $57.3 million compared to $38.0 million for the same period of fiscal 2021 . • Cost of Revenues: Cost of revenues for the fourth quarter of fiscal 2022 was $31.6 million compared to $22.5 million for the same period of fiscal 2021 . • Research and Development Expenses: Research and development expenses for the fourth quarter of fiscal 2022 were $29.6 million compared to $19.4 million for the same period of fiscal 2021 . • Selling, General and Administrative Expenses: Selling, general and administrative expenses for the fourth quarter of fiscal 2022 were $54.2 million compared to $38.2 million for the same period of fiscal 2021 . • Net Loss: Net loss attributable to common stockholders for the fourth quarter of fiscal 2022 wa
  evidence_url: https://www.sec.gov/Archives/edgar/data/1581280/000162828022030393/0001628280-22-030393-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.